September 3, 2019 08:29 AM EDT

AstraZeneca's diabetes drug Farxiga cuts risk of CV death or worsening of heart failure by 26% in landmark study

Natalie Grover

Reporter

About two weeks after AstraZeneca’s $AZN unveiled its diabetes treatment Farxiga cut the risk of CV death or the worsening of heart failure in patients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca's diabetes drug Farxiga cuts risk of CV death or worsening of heart failure by 26% in landmark study

Natalie Grover

Reporter

Sign up to read this article for free.

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Exclusive: Florida cancer biotech raises $100M Series A

As­traZeneca's di­a­betes drug Farx­i­ga cuts risk of CV death or wors­en­ing of heart fail­ure by 26% in land­mark study

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

AstraZeneca's diabetes drug Farxiga cuts risk of CV death or worsening of heart failure by 26% in landmark study

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Exclusive: Florida cancer biotech raises $100M Series A